<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906828</url>
  </required_header>
  <id_info>
    <org_study_id>DuoCOMT</org_study_id>
    <nct_id>NCT00906828</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Levodopa/Carbidopa Infusion With and Without Oral Catechol-O-methyl Transferase (COMT) Inhibitors</brief_title>
  <acronym>DuoCOMT</acronym>
  <official_title>Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Parkinson's Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Society for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral intake of COMT inhibitors affects the
      smooth plasma levodopa levels achieved by intestinal levodopa/carbidopa infusion in advanced
      Parkinson's disease patients. The hypothesis is that COMT inhibitors make plasma
      concentrations of levodopa more fluctuating.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim is to measure variability in plasma levodopa levels during the following three
      treatments:

      Day 1: Duodopa in individually optimised dose Day 2: 80% of optimised Duodopa dose + two
      tablets of entacapone at t=0 hours and at t= 6 hours Day 3: 80% of optimised Duodopa dose +
      two tablets of tolcapone at t=0 hours and at t= 6 hours Plasma samples for determination of
      levodopa concentrations will be taken every 30 minutes during 8 hours. Video recordings will
      be performed every 30 min during 8 hours, for later blinded assessments by 2-3 experts.
      Sequences will be in randomised order. Patient self-scores regarding mobility will be
      recorded, every 30 min during 8 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in coefficient of variation of levodopa in plasma between baseline (day 1) and each of the days on COMT inhibitors.</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Treatment Response Scale between the treatments.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>1. Duodopa, optimised dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. 80% Duodopa + entacapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. 80% Duodopa + tolcapone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa/carbidopa</intervention_name>
    <description>intestinal gel, continuous infusion (daytime or 24-hour)</description>
    <arm_group_label>1. Duodopa, optimised dose</arm_group_label>
    <other_name>Duodopa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entacapone</intervention_name>
    <description>Tablet, 200 mg, given twice during the study at t=0h and t=5hrs</description>
    <arm_group_label>2. 80% Duodopa + entacapone</arm_group_label>
    <other_name>Comtess, Comtan.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolcapone</intervention_name>
    <description>Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.</description>
    <arm_group_label>3. 80% Duodopa + tolcapone</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease

          -  Duodopa treatment ongoing

          -  Hoehn &amp; Yahr stage 3-5 at worst

        Exclusion Criteria:

          -  Ongoing treatment with COMT inhibitors

          -  Dementia

          -  Psychosis

          -  Treatment with typical neuroleptics

          -  Contraindications for entacapone or tolcapone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Nyholm, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75646</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother. 2006 Oct;6(10):1403-11. Review.</citation>
    <PMID>17078781</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dag Nyholm, MD, PhD</name_title>
    <organization>Uppsala University</organization>
  </responsible_party>
  <keyword>Levodopa/carbidopa infusion</keyword>
  <keyword>entacapone</keyword>
  <keyword>tolcapone</keyword>
  <keyword>efficacy</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Entacapone</mesh_term>
    <mesh_term>Tolcapone</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Catechol O-Methyltransferase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

